Desoxipipradrol. Fármacos antiguos, problemas nuevos
- Elena Durán
- Marta Mosquera
- Cristina Ruiz
- Fernando Bandrés Moya
- Francesc Campos
- Bartomeu Castanyer Puig
- Carmen Farré Masip
- Juan Fernando Izquierdo
- Elena Llorente
- Jordi To-Figueras
- Salvador Ventura Pedret
- Josep M. Queraltó Compañó
ISSN: 1888-4008
Year of publication: 2015
Volume: 8
Issue: 1
Pages: 29-38
Type: Article
More publications in: Revista del laboratorio clínico
Sustainable development goals
Abstract
Stimulant substances previously used for therapeutic purposes, and are currently banned, have recently been marketed through the Internet. These drugs, structurally similar to neurotransmitters, can potentially cause severe clinical conditions. Exposure to these “legal highs” results in symptoms similar to those of well-known substances such as phencyclidine, amphetamines or cocaine, probably because they share mechanisms of action related to dopamine reuptake in brain nuclei involved in the regulation of reward behavior. The limitations of medical evidence, as well as difficulties in obtaining calibration material, constitute an analytical challenge. Desoxypipradol was synthesized more than six decades ago for the treatment of hyperkinetic disorder, but was surpassed by methylphenidate, a similar compound with a better pharmacokinetic performance. In 2009 desoxypipradol appeared as a recreational drug involved in several cases of clinical intoxication.